



KERALA MEDICAL SERVICES CORPORATION LTD.,
(Dept. of Health & Family Welfare, Govt. of Kerala)

Thycaud P.O., Thiruvananthapuram-14

Tele Fax No : 0471-2945647,

0471-2337353, 0471-2945600

Email id : edrugs.kmscl@kerala.gov.in

CIN : U24233KL2007SGC021616

Essential Drugs Division

KMSCL/ED/81/2024

www.kmscl.kerala.gov.in

Date: 29.10.2025

NOTICE

Anti-Cancer Drugs

Sub :- KMSCL – E-tender for the Procurement of Anti-Cancer Drugs for the year 2025-26 – Change in GST– Revised Final Bid Status Published - Reg:-

- Ref :-
1. E-tender No. KMSCL/ED/ACD/RC/2024/034 Dated 27.12.2024.
 2. E-tender No. KMSCL/ED/ACD/RT/2025/016 Dated 03.07.2025.
 3. E-tender No. KMSCL/ED/ACD/RT/2025/021 Dated 16.07.2025.
 4. This Office Notice No. KMSCL/ED/81/2024 Dated 17.07.2025 on Final Bid Status.
 5. This Office Notice No. KMSCL/ED/7-RT/2025 Dated 23.08.2025 & 01.09.2025 on Final Bid Status.
 6. Recommendations of the 56th Meeting of GST council held on 03.09.2025.

The Price Bids (BOQ) submitted online in response to the e-tender's referred 1st to 3rd above for the Procurement of Anti-Cancer Drugs for the year 2025-26 were opened and the final Bid Status of the same was published vide notice referred 4th & 5th cited.

As per the recommendations of the 56th GST Council meeting held on 3rd September 2025, reforms Next-Gen GST aiming to simplify tax slabs and reduce rates on many goods and services, for facilitation of trade and the new rates will be effective from 22nd September 2025.

In this regard, the rates/price bid status of the above referred tenders are corrected with the revised GST%, GST values & landed price and is revised accordingly without any change in the Basic price offered.

The revised rates against the tender referred 1st to 3rd cited are published herewith as **Annexure I, II, & III.**

The rates published will be applicable to all the purchase orders issued and the invoices received from the supplier with effect from 22nd September 2025.

All the suppliers are requested to verify their prices in the Annexures and discrepancies, if any, noted in the same shall be submitted by e-mail edrugs.kmscl@kerala.gov.in on or before 05.00 pm on 30.10.2025.

All the suppliers are directed to furnish an Undertaking/ Declaration of acceptance of revised rates in the format prescribed in **Annexure IV**.

Sd/-

MANAGING DIRECTOR
KERALA MEDICAL SERVICES CORPORATION LTD.
(TENDER INVITING AUTHORITY)

**FINAL BID STATUS FOR THE E-TENDER FOR THE PROCUREMENT OF ANTI CANCER
DRUGS FOR THE YEAR 2025-26**

(Tender No: KMSCL/ED/ACD/RC/2024/034 Dated 27.12.2024)

Sl No	Drug Code	Drug Name	Strengt h	Unit	Revised GST as on 22.09.2025	SUPPLIE R NAME	BASIC PRICE	CGST	SGST	IGST	Revised Final Rate	Stat us
1	D24170C	ABIRATER ONE ACETATE TAB IP	250 mg	1 no	5	Admac Life Sciences	25			1.2500	26.2500	L1
2	D24170C	ABIRATER ONE ACETATE TAB IP	250 mg	1 no	5	MSN Laboratori es Pvt Ltd	25			1.2500	26.2500	L1
3	D24058C	ANASTRAZ OLE TAB IP	1mg	1 No	5	Admac Life Sciences	1.3			0.0650	1.3650	L1
4	D24059C	BENDAMUS TINE INJ IP	100mg	Vial	5	Beta Drugs Limited	780			39.0000	819.0000	L1
5	D24298C	BEVACIZU MAB INJ	400mg	vial	5	Dr.Reddys Laboratori es Limited	4996	124.9000	124.9000		5,245.8000	L1
6	D24060C	BEVACIZU MAB INJ.	100mg	Vial	5	Dr.Reddys Laboratori es Limited	1389	34.7250	34.7250		1,458.4500	L1
7	D24061C	BICALUTA MIDE TAB IP	50mg	1 No	5	Admac Life Sciences	3.9			0.1950	4.0950	L1
8	D24062C	BLEOMYCI N INJ IP	15 Units	Vial	5	Khandelw al Laboratori es Pvt Ltd	436.95			21.8475	458.7975	L1
9	D24063C	BORTEZOM IB INJ IP	2mg	Vial	5	Beta Drugs Limited	218			10.9000	228.9000	L1
10	D24066C	CAPECITAB INE TAB IP	500mg	1 No	5	Reliance Life Sciences Pvt Ltd	9.5			0.4750	9.9750	L1
11	D24067C	CARBOPLA TIN INJ IP	150mg	Vial	5	Admac Life Sciences	420			21.0000	441.0000	L1
12	D24068C	CARBOPLA TIN INJ IP	450mg	Vial	5	Admac Life Sciences	1180			59.0000	1,239.0000	L1
13	D24069C	CETUXIMA B INJ	100mg	Vial	5	ENZENE BIOSCIE NCES LIMITED	5800			290.0000	6,090.0000	L1
14	D24071C	CISPLATIN INJ IP	10mg	Vial	5	Khandelw al Laboratori es Pvt Ltd	55			2.7500	57.7500	L1
15	D24072C	CISPLATIN INJ IP	50mg	Vial	5	Khandelw al Laboratori es Pvt Ltd	215			10.7500	225.7500	L1
16	D24077C	CYTARABI NE INJ IP/BP	100mg	Vial	5	Khandelw al Laboratori es Pvt Ltd	40			2.0000	42.0000	L1
17	D24079C	DASATINIB TAB	20mg	1 No	5	Admac Life Sciences	5.8			0.2900	6.0900	L1
18	D24080C	DASATINIB	50mg	1 No	5	Admac	12.7			0.6350	13.3350	L1

Sl No	Drug Code	Drug Name	Strengt h	Unit	Revised GST as on 22.09.2025	SUPPLIE R NAME	BASIC PRICE	CGST	SGST	IGST	Revised Final Rate	Stat us
		TAB				Life Sciences						
19	D24082C	DOCETAXE L INJ IP	20mg	Vial	5	Beta Drugs Limited	80			4.0000	84.0000	L1
20	D24083C	DOCETAXE L INJ IP	80mg	Vial	5	Beta Drugs Limited	258			12.9000	270.9000	L1
21	D24084C	DOCETAXE L INJ IP	120mg	Vial	5	Beta Drugs Limited	358			17.9000	375.9000	L1
22	D24090C	DOXORUBI CIN (PEGYLATE D LIPOSOMA L) INJ	20 mg	Vial	5	Intas Pharmace uticals Ltd	606			30.3000	636.3000	L1
23	D24091C	DOXORUBI CIN (PEGYLATE D LIPOSOMA L) INJ	50mg	Vial	5	Intas Pharmace uticals Ltd	1046			52.3000	1,098.3000	L1
24	D24087C	DOXORUBI CIN INJ (LYOPHILIS ED) IP	10mg	Vial	5	Beta Drugs Limited	48			2.4000	50.4000	L1
25	D24088C	DOXORUBI CIN INJ (LYOPHILIS ED) IP	50mg	Vial	5	Beta Drugs Limited	143			7.1500	150.1500	L1
26	D24092C	EPIRUBICIN INJ IP	10mg	Vial	5	Beta Drugs Limited	98			4.9000	102.9000	L1
27	D24093C	EPIRUBICIN INJ IP	50mg	Vial	5	Beta Drugs Limited	388			19.4000	407.4000	L1
28	D24094C	ERLOTINIB TAB IP	100mg	1 No	5	Beta Drugs Limited	18			0.9000	18.9000	L1
29	D24095C	ERLOTINIB TAB IP	150mg	1 No	5	Beta Drugs Limited	21			1.0500	22.0500	L1
30	D24096C	ETOPOSID E CAP IP	50mg	1 No	5	Adley Formulati ons	38			1.9000	39.9000	L1
31	D24097C	ETOPOSID E INJ IP	100mg	Vial	5	Adley Formulati ons	96			4.8000	100.8000	L1
32	D24294C	FERRIC CARBOXY MALTOSE INJ	1gm/20ml	vial	5	Bharat Serums and Vaccines Ltd.	750	18.7500	18.7500		787.5000	L1
33	D24228C	FILGRASTI M INJ IP	300 mcg	PFS	5	Reliance Life Sciences Pvt Ltd	95			4.7500	99.7500	L1
34	D24102C	FULVESTR ANT INJ	250mg	Vial/P FS	5	Therdose Pharma Pvt Ltd	2100			105.0000	2,205.0000	L1
35	D24103C	GEFITINIB TAB IP	250mg	1 No	5	Khandelw al Laboratori es Pvt Ltd	10.72			0.5360	11.2560	L1
36	D24104C	GEMCITABI NE INJ IP	200mg	Vial	5	Beta Drugs Limited	80			4.0000	84.0000	L1
37	D24105C	GEMCITABI NE INJ IP.	1gm	Vial	5	Beta Drugs	318			15.9000	333.9000	L1

Sl No	Drug Code	Drug Name	Strengt h	Unit	Revised GST as on 22.09.2025	SUPPLIE R NAME	BASIC PRICE	CGST	SGST	IGST	Revised Final Rate	Stat us
						Limited						
38	D24165C	IMATINIB TAB IP	100 mg	1 No	5	Admac Life Sciences	6			0.3000	6.3000	L1
39	D24164C	IMATINIB TAB IP	400 mg	1 No	5	Admac Life Sciences	11			0.5500	11.5500	L1
40	D24115C	IRINOTECA N INJ IP	40mg	Vial	5	Adley Formulati ons	118			5.9000	123.9000	L1
41	D24116C	IRINOTECA N INJ IP	100mg	Vial	5	Adley Formulati ons	268			13.4000	281.4000	L1
42	D24117C	L.ASPARAG INASE INJ	5000 IU	Vial	5	Beta Drugs Limited	338			16.9000	354.9000	L1
43	D24119C	LENALIDO MIDE CAP	10mg	1 No	5	Admac Life Sciences	10			0.5000	10.5000	L1
44	D24163C	LENALIDO MIDE CAP	5mg	1 No	5	Admac Life Sciences	50			2.5000	52.5000	L1
45	D24120C	LETROZOL E TAB IP/USP	2.5mg	1 No	5	Khandelw al Laboratori es Pvt Ltd	0.82			0.0410	0.8610	L1
46	D24065C	LEUCOVOR IN CALCIUM INJ IP	50mg	Vial	5	Admac Life Sciences	26.5			1.3250	27.8250	L1
47	D24121C	LEUPROLID E ACETATE INJ	3.75m g	Vial	5	Bharat Serums and Vaccines Ltd.	1090	27.2500	27.2500		1,144.5000	L1
48	D24122C	LEUPROLID E ACETATE INJ	11.25 mg	Vial	5	Bharat Serums and Vaccines Ltd.	4340	108.5000	108.5000		4,557.0000	L1
49	D24250C	LEUPROLID E ACETATE INJ	22.5 mg	vial	5	Bharat Serums and Vaccines Ltd.	6980	174.5000	174.5000		7,329.0000	L1
50	D24198C	MERCAPTO PURINE TAB IP	50 mg	1 no	5	Globela Pharma Pvt Ltd	4.5			0.2250	4.7250	L1
51	D24127C	METHOTRE XATE INJ IP	50mg	Vial	5	Admac Life Sciences	24			1.2000	25.2000	L1
52	D24128C	METHOTRE XATE TAB IP	2.5mg	1 No	5	Globela Pharma Pvt Ltd	2.2			0.1100	2.3100	L1
53	D24133C	OXALIPLAT IN INJ IP	50mg	Vial	5	Khandelw al Laboratori es Pvt Ltd	197			9.8500	206.8500	L1
54	D24134C	OXALIPLAT IN INJ IP	100mg	Vial	5	Khandelw al Laboratori es Pvt Ltd	377.5			18.8750	396.3750	L1
55	D24136C	PACLITAXE L INJ IP	30mg	Vial	5	Khandelw al Laboratori es Pvt Ltd	86			4.3000	90.3000	L1
56	D24137C	PACLITAXE L INJ IP WITH	100mg	Vial	5	Khandelw al Laborat ories Pvt	349			17.4500	366.4500	L1

Sl No	Drug Code	Drug Name	Strength	Unit	Revised GST as on 22.09.2025	SUPPLIER NAME	BASIC PRICE	CGST	SGST	IGST	Revised Final Rate	Status
		CODON SET				Ltd						
57	D24138C	PACLITAXEL INJ IP WITH CODON SET	260mg	Vial	5	Khandelwal Laboratories Pvt Ltd	549.8			27.4900	577.2900	L1
58	D24207C	PAZOPANIB TAB	400 mg	1 no	5	Beta Drugs Limited	68			3.4000	71.4000	L1
59	D24140C	PEGFILGRASTIM INJ	6mg	Vial/PFS	5	Reliance Life Sciences Pvt Ltd	810			40.5000	850.5000	L1
60	D24141C	PEMETREXED INJ IP	100mg	Vial	5	SHILPA MEDICARE LTD	118.8			5.9400	124.7400	L1
61	D24142C	PEMETREXED INJ IP.	500mg	Vial	5	SHILPA MEDICARE LTD	433			21.6500	454.6500	L1
62	D24146C	RITUXIMAB INJ	500mg	Vial	5	Reliance Life Sciences Pvt Ltd	4420			221.0000	4,641.0000	L1
63	D24145C	RITUXIMAB INJ.	100mg	Vial	5	Reliance Life Sciences Pvt Ltd	910			45.5000	955.5000	L1
64	D24147C	SORAFENIB TOSYLATE TAB IP	200mg	1 No	5	Beta Drugs Limited	14			0.7000	14.7000	L1
65	D24216C	SUNITINIB CAP	12.5 mg	1 no	5	Admac Life Sciences	17.95			0.8975	18.8475	L1
66	D24150C	TAMOXIFEN TAB IP	20mg	1 No	5	Admac Life Sciences	1.2			0.0600	1.2600	L1
67	D24150C	TAMOXIFEN TAB IP	20mg	1 No	5	Khandelwal Laboratories Pvt Ltd	1.2			0.0600	1.2600	L1
68	D24152C	TEMOZOLOMIDE CAP IP	100mg	1 No	5	Beta Drugs Limited	28			1.4000	29.4000	L1
69	D24153C	TEMOZOLOMIDE CAP IP	250mg	1 No	5	Beta Drugs Limited	90			4.5000	94.5000	L1
70	D24154C	THALIDOMIDE CAP USP	100mg	1 No	5	Admac Life Sciences	7			0.3500	7.3500	L1
71	D24269C	TRASTUZUMAB INJ	150 MG	Vial	5	Reliance Life Sciences Pvt Ltd	1990			99.5000	2,089.5000	L1
72	D24156C	TRASTUZUMAB INJ.	440mg	Vial	5	Reliance Life Sciences Pvt Ltd	5300			265.0000	5,565.0000	L1
73	D24160C	ZOLEDRONIC ACID INJ IP	4mg	Vial	5	Khandelwal Laboratories Pvt Ltd	35			1.7500	36.7500	L1

Sd/-
MANAGING DIRECTOR

ANNEXURE-II

**FINAL BID STATUS FOR THE RE-TENDER FOR THE PROCUREMENT OF ANTI CANCER
DRUGS FOR THE YEAR 2025-26**

(Tender No: KMSCL/ED/ACD/RT/2025/016 DATED 03.07.2025)

Sl No	Drug Code	Drug Name	Strength	Unit	Supplier Name	Revised GST as on 22.09.2025	Basic Price	CGST	SGST	IGST	Revised Final Rate	Status
1	D24111C	IFOSFAMIDE WITH MESNA INJ	2gm	Vial	Albino Lifesciences Pvt Ltd	5	519.3			25.9650	545.2650	L1
2	D24110C	IFOSFAMIDE WITH MESNA INJ	1gm	Vial	Albino Lifesciences Pvt Ltd	5	249.3			12.4650	261.7650	L1

Sd/-

MANAGING DIRECTOR

ANNEXURE-III

**FINAL BID STATUS FOR THE RE-TENDER FOR THE PROCUREMENT OF ANTI CANCER
DRUGS FOR THE YEAR 2025-26**

(Tender No: KMSCL/ED/ACD/RT/2025/021 Dated 16.07.2025)

Sl No	Drug Code	Drug Name	Strength	Unit	Supplier Name	Revised GST as on 22.09.2025	Basic Price	CGST	SGST	IGST	Revised Final Rate	Status
1	D24231C	CARFILZOMIB INJ	30 mg	Vial	Dr.Reddys Laboratories Limited	5	16,327.00	408.1750	408.1750		17,143.3500	L1
2	D24190C	ERIBULIN INJ	0.44 mg/ml	2 ml Vial	Emcure Pharmaceuticals Ltd	5	6,500.00	162.5000	162.5000		6,825.0000	L1
3	D24118C	LAPATINIB TAB IP	250mg	1 No	Bruck Pharma Pvt Ltd	5	49.00			2.4500	51.4500	L1
4	D24255C	PACLITAXEL NANOPARTICLE INJ	100mg	vial	Fresenius Kabi Oncology Ltd	5	3,858.00			192.9000	4,050.9000	L1
5	D24144C	PROTEIN BOUND PACLITAXEL INJ	100mg	Vial	Beta Drugs Limited	5	1,338.00			66.9000	1,404.9000	L1

Sd/-

MANAGING DIRECTOR

DECLARATION AND UNDERTAKING ON ACCEPTANCE OF REVISED RATES

With reference to the notice published **Dated:**..... we hereby acknowledge the receipt of the communication regarding the revision of rates against the e-tenders for the year **2025-26** floated by the Kerala Medical Services Corporation Ltd., Thiruvananthapuram pursuant to the recommendations of the 56th GST Council meeting held on 03.09.2025.

I/We, Sole Proprietor/Managing Partner/Managing Director/Power of Attorney holder of **M/s.**_____ having its Registered Office/ Place of business at _____ and having Factory Premise(s) at _____ & _____ do hereby declare on oath as follows;

1. That I/we have carefully verified the revised rates published against the **E-Tender No****Dated**..... floated by the Kerala Medical Services Corporation Ltd., Thiruvananthapuram and undertake to execute the supply as per the terms and conditions of the Tender document including amendments of the tender published by the Corporation with the revised rates therein.
2. I/we further declare that no additional claims or charges shall be made on account of this revision, and I/we shall abide by all other terms and conditions stipulated in the original contract agreement.

Thanking you,

(Signature, Name & Designation)

Witness:

1. (Name, Address & Signature)

2. (Name, Address & Signature)

Seal